Mato, A., Burris, H. A., Flinn, I., Lunning, M., Vose, J., Fowler, N., … O’Connor, O. A. (2016). LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In HAEMATOLOGICA (Vol. 101, pp. 50–51). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.

Mato, A., H. A. Burris, I. Flinn, M. Lunning, J. Vose, N. Fowler, L. Nastoupil, et al. “LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.” In HAEMATOLOGICA, 101:50–51. FERRATA STORTI FOUNDATION, 2016.

Mato A, Burris HA, Flinn I, Lunning M, Vose J, Fowler N, et al. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 50–1.

Mato, A., et al. “LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.” HAEMATOLOGICA, vol. 101, FERRATA STORTI FOUNDATION, 2016, pp. 50–51.

Mato A, Burris HA, Flinn I, Lunning M, Vose J, Fowler N, Nastoupil L, O’Brien S, Schreeder MT, Patel MR, Fenske TS, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin H, Weiss MS, O’Connor OA. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 50–51.